Despite some studies reporting comparable OHSS rates [Ganirelix: 8.0% (7/87) vs. Cetrorelix: 6.8% (6/88)] (17) and similar trigger-day E2 levels/oocyte yields (18), Cetrorelix consistently demonstrated lower severe OHSS incidence [0.6% in literature (19); 0.084% in our trial], potentially attributable to its shorter half-life and transient LH suppression (18). This evidence concerns the gene PLOD1 and ovarian hyperstimulation syndrome.